InvestorLens

BCAB — BIOATLA INC

Public company

Sign in to save1 tracked investor reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying BCAB?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 2 selling last quarter
2
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their BCAB position last quarter, 0 bought and 2 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +1 tracked investors reported holding BCAB at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About BIOATLA INC (BCAB)

BIOATLA INC (BCAB) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $5M. Across recent filings, tracked investors recorded 3 new positions, 3 increased, 6 reduced, and 4 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in BCAB

38
/100
Institutional Distribution
Added / Increased6
Reduced6
Exited4
BearishBullish
Crowded Trade Score™

How many top investors track BCAB

7
/100
Undiscovered
1investor

Only 1 tracked investor report this position.

UndiscoveredCrowded
151015+

BCAB Ownership Composition

How BIOATLA INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
1
tracked investors
Total Reported
$292.4K
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(1)
100.0%

Tracked investors currently reporting BCAB

2 tracked investors have since exited this position — listed separately below.

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    70.6K
    Value
    $292.4K
    % Portfolio
    0.00%

Previously held BCAB

These investors reported BCAB in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Michael BurryScion Asset Management634K$868.5KJun 30, 2024
Ken GriffinCitadel Advisors473.6K$76.2KMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold BCAB?
1 tracked institutional investor disclosed a position in BCAB (BIOATLA INC) in their most recent 13F filing.
Who is the largest institutional holder of BCAB?
Izzy Englander, Millennium Management, holds the largest disclosed position in BCAB, valued at $5M.
Did institutional ownership of BCAB increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 3 increased, 6 reduced, and 4 fully exited BCAB.
Where does this BCAB ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.